Semaglutide and tirzepatide are both injectable medications used to support weight loss and metabolic health, but they don't work the same way. Understanding the difference helps set realistic expectations — and helps you and your clinician choose the tool that fits your body, budget, and goals.
Both are administered as a small once-weekly subcutaneous injection, both were first developed for type 2 diabetes, and both have since been approved for chronic weight management. From there, they diverge.
Semaglutide
- Acts on a single receptor — GLP-1
- Strong appetite suppression and improved glucose control
- Studied for years for type 2 diabetes (Ozempic) and weight management (Wegovy)
- Average weight loss in clinical studies: roughly 12–15% of body weight over a year
- Well-established cardiovascular benefit data in patients with diabetes
- Generally milder side-effect intensity than tirzepatide, especially early on
Tirzepatide
- Acts on two receptors — GLP-1 and GIP
- Often produces stronger appetite reduction and greater weight loss
- Marketed as Mounjaro (diabetes) and Zepbound (weight management)
- Average weight loss in clinical studies: roughly 18–22% of body weight at higher doses
- May have greater impact on visceral fat and metabolic markers
- Side effects can be more pronounced during dose increases
Why the second receptor (GIP) matters
GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone released after meals. When tirzepatide activates both GLP-1 and GIP receptors, the metabolic effect is broader — more appetite suppression, better insulin sensitivity, and, in many patients, better tolerance of the appetite drop over time.
That dual-action design is why average weight loss numbers run higher for tirzepatide in head-to-head data. But 'higher average' doesn't mean 'right for everyone.' Individual response varies widely, and many clients hit their goals on semaglutide with fewer side effects.
How to think about choosing
Bigger results in a trial don't automatically mean a better fit for you. Tolerance, side effect profile, cost, insurance coverage, dosing flexibility, and your medical history all shape the right choice. Many clients respond well to either; others tolerate one much better than the other.
Cost and access have historically favored semaglutide, though the market shifts often. Some clients start on one and switch later based on tolerance or plateau. Others stay on their initial choice for years.
If you experience side effects or symptoms that concern you while on either medication, contact your EllieMD physician directly through the EllieMD Client Portal.
This is a clinical decision, not a search-engine decision. A consultation reviews your labs, history, and goals so the recommendation is genuinely tailored — and the plan around it (protein, strength training, sleep, stress) is what determines whether the results actually last.